REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Preparations Characterized By Special Physical Form > Liposomes LiposomesLiposomes patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178147 - Liposomal compositions This invention relates generally to liposomal pharmaceutical compositions and related methods. ... 07/26/07 - 20070172520 - Immunotargeting of nonionic surfactant vesicles An immunoniosmes for targeted delivery of therapeutic agents to specific tissues in a host and methods of synthesis of those niosomes. An antibody molecule having specificity for a target antigen, such as a cell surface marker or other marker differentially expressed on a target cell, is covalently coupled to a ... 07/19/07 - 20070166368 - Protein-stabilized liposomal formulations of pharmaceutical agents The present invention relates to protein stabilized liposomes. Specifically, the present invention discloses compositions and methods for protein stabilized liposomes, the creation of protein stabilized liposomes, and the administration of protein stabilized liposomes. ... 07/19/07 - 20070166367 - Adept or gdept producing acetaldehyde The present invention includes compounds, comprising a portion capable of converting a substrate, for example ethanol, to acetaldehyde and a means of directing the compounds to selected cells, and their use in therapeutic compositions and methods. The compounds may be administered with the substrate, for example ethanol, and an inhibitor ... 07/19/07 - 20070166366 - Autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells The present invention provides methods for high level, regulated transgene transcription that is restricted to cell populations of specific types. The process is designed to work with any inducible expression regulation systems, adapting them to a tissue-specific expression pattern while simultaneously delivering maximal achievable expression levels. In particular, the invention ... 07/12/07 - 20070160658 - Delivery system for diagnostic and therapeutic agents Nanovesicles are specifically targeted to abnormal cells. The targeting moiety is conjugated to the nanovesicle which comprises a therapeutic composition. These nanovesicles are useful in treatment of a wide spectrum of disorders. ... 07/12/07 - 20070160657 - Targeting and intestinal-absorption controlled liposome having sugar chain and therapeutic drug for cancer and diagnostic drug containing the liposome An object of the present invention is to provide a liposome having a sugar chain bonded thereto, the sugar chain having an activity of specifically binding to various lectins (sugar chain recognizing proteins) present on the cell surfaces of various tissues and thus being capable of actually distinguishing a cell ... 07/12/07 - 20070160656 - Lipid platinum complexes and methods of use thereof This invention provides novel lipid platinum complexes, liposomally encapsulated lipid platinum complexes, pharmaceutical compositions comprising a lipid platinum complex, and methods for treating cancer using a lipid platinum complex. Kits comprising a unit dosage form of a compound or composition of the invention are also provided. ... 07/05/07 - 20070154538 - Removal of fat cells by pdt A non-surgical, minimally invasive PhotoDynamic Therapy (PDT) method for destruction of undesirable fat cells in the body, which cause obesity, obesity related health problems, and undesirable body contours. In this method photosensitizing agents are formulated into a liposomal formulation or into other delivery means for administering the drug systemically, directly ... 07/05/07 - 20070154537 - Lipid-derivatized bisphosphonic acid as well as their physiologically compatible derivatives, in particular salts and trimethyl silyl derivatives. ... 06/28/07 - 20070148226 - Mahonia aquifolim extract, extraction process and pharmaceutical composition containing the same The present invention provides a skin treatment composition comprising a Mahonia aquifolium extract in a liposome delivery system. The Mahonia aquifolium extract is present in the skin treatment composition in a range of from 5% to 20% by weight of the total composition. The skin treatment composition is particularly effective ... 06/28/07 - 20070148225 - Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye The present invention relates to development of efficacious pharmaceutical compositions comprising an active compound in a therapeutically effective amount encapsulated or solubilized in phospholipid vesicles. ... 06/28/07 - 20070148223 - Skin treatment compositions containing copper-pigment complexes A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the ... 06/28/07 - 20070148222 - Skin treatment compositions containing copper-pigment complexes A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the ... 06/28/07 - 20070148221 - Method of producing lipid complexed camptothecin-carboxylate An improved method for producing a cationic liposomal preparation comprising a camptothecin drug with enhanced physical and chemical stability, a cationic liposomal preparation obtainable by this method and pharmaceutical compositions thereof are disclosed. ... 06/28/07 - 20070148220 - Liposomes and liposomal compositions for vaccination and drug delivery The present invention relates to liposomes and compositions comprising liposomes, their production and use for the prevention and therapy of proliferative diseases, infectious diseases, vascular diseases, rheumatoid diseases, inflammatory diseases, immune diseases, and allergies. ... 06/21/07 - 20070141136 - Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in a mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension ... 06/21/07 - 20070141135 - Compositions and methods for less immunogenic protein-lipid complexes The present invention provides compositions and methods for reducing the immunogenicity and increasing the circulating half-life of therapeutic proteins such as Factor VIII. The compositions comprise lipidic structures such as liposomes, micelles and cochleates comprising a negatively charged lipid and polyethylene glycol derivatized phospatidyl ethanolamine. ... 06/21/07 - 20070141134 - Shielded micelles for polynucleotide delivery The present invention relates to compositions that enhance the intracellular delivery of polynucleotides. The present invention is applicable to the fields of gene therapy and oligonucleotide or DNA therapy. Synthetic methods are disclosed, wherein a polynucleotide can be incorporated into the PEG shielded micelle particle to facilitate the delivery of ... 06/21/07 - 20070141133 - Glutathione based delivery system A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded ... 06/14/07 - 20070134314 - Therapeutic inhibitor of vascular smooth muscle cells Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle ... 06/14/07 - 20070134313 - Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention ... 06/14/07 - 20070134312 - Liposomes for treatment of multiple myeloma A method for treating multiple myeloma in newly diagnosed or previously treated patients is described. The method comprises administering a composition consisting of a combination of chemotherapeutic agents of an anthracycline antibiothic, preferably entrapped in a liposome, dexamethasone, and thalidomide, and, optionally, a reduced dose of vincristine. ... 06/07/07 - 20070128265 - Regulation of cell proliferation and differentiation using topically applied peptides Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorders, such as psoriasis, for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by topical administration of parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and ... 05/31/07 - 20070122469 - Method for producing a vesicle dispersion A method for preparing a vesicle dispersion wherein a water-soluble substance is encupsulated in the vesicle, which comprises successively performing: a step of dispersing at least one lipid in an aqueous medium to pre-construct a vesicle dispersion, a step of drying the pre-constructed vesicles to obtain dried vesicles, a step ... 05/31/07 - 20070122468 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts ... 05/31/07 - 20070122467 - Anaesthetic formulations Propofol Solubilised in aqueous micellar preparations of poloxamers is stable at low concentrations and that such preparations are effective administration forms for Propofol. ... 05/31/07 - 20070122466 - Sphingomyelin liposomes for the treatment of hyperactive bladder disorders The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in ... 05/31/07 - 20070122465 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts ... 05/31/07 - 20070122464 - Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, as well as their pharmacologically compatible salts and/or derivatives having equivalent effects, for producing dermatological preparations such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of ... 05/24/07 - 20070116755 - Dissolution of arterial cholesterol plaques by pharmacological preparation A pharmacological substance namely a biliary salt or acid or precursor or derivative with emulsifying properties administered into the systemic circulation of a patient via a variety of routes of administration including topical-mucous membrane such as sublingual, topical-dermatological such as via a skin patch, intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory ... 05/24/07 - 20070116754 - Dissolution of arterial cholesterol plaques by pharmacological preparation A pharmacological substance namely a biliary salt or acid or precursor or derivative with emulsifying properties administered into the systemic circulation of a patient via a variety of routes of administration including topical-mucous membrane such as sublingual, topical-dermatological such as via a skin patch, intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory ... 05/24/07 - 20070116753 - Liposomes useful for drug delivery The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. ... 05/17/07 - 20070110798 - Liposomes useful for drug delivery to the brain The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of ... 05/10/07 - 20070104777 - Targeted liposomal drug delivery system A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use. ... 05/10/07 - 20070104776 - Drug having regulatory cell ligand contained in liposome A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc. ... 05/10/07 - 20070104775 - Amphoteric liposomes A serum-stable mixture of lipids capable of encapsulating an active agent to form a liposome, said mixture comprising phosphatidylcholine and phosphatidylethanolamine in a ratio in the range of about 0.5 to about 8. The mixture may also include pH sensitive anionic and cationic amphiphiles, such that the mixture is amphoteric, ... 05/10/07 - 20070104774 - Method for preparing phytosphingosine liposome composition The invention relates to a method for preparing phytosphingosine liposome composition having excellent long-term storage stability and the method comprises dispersing phytosphingosine in water, separately dissolving phospholipid in a solvent and mixing the two solutions prepared by the above procedures. ... 05/03/07 - 20070098777 - Pharmaceutical or food composition for treatment or prevention of brain edema Melatonin has an activity of treating or preventing brain edema. Thus, the invention relates to a pharmaceutical composition comprising melatonin as an active ingredient. And, the invention relates to use of melatonin in the preparation of a pharmaceutical composition comprising melatonin as an active ingredient. ... 05/03/07 - 20070098776 - Hla class i a2 tumor associated antigen peptides and vaccine compositions A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6. ... 04/26/07 - 20070092558 - Methods of preparing targeted immunoliposomes Methods of preparing targeting ligand bound avidin-lipid vesicles for use in preparing a targeted, therapeutic liposome composition are disclosed. Each vesicle comprises an avidin molecule coupled to the polymer-conjugated biotin which retains multiple free site biotin-binding sites such that the vesicle may be used to further couple a biotinylated-targeting ligand. ... 04/19/07 - 20070087047 - Enhanced circulation effector composition and method A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment ... 04/19/07 - 20070087046 - Use of green porphyrins to treat neovasculature in the eye Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions. ... 04/19/07 - 20070087045 - Lipid carrier and method of preparing the same A lipid carrier. The carrier includes a lipid based particle comprising a cationic lipid, a cholesterol, a neutral phospholipid, and a neutral lipid, wherein the cationic lipid is about 100 parts by weight, the cholesterol is about 25˜100 parts by weight, the neutral phospholipid is about 25˜100 parts by weight, ... 04/12/07 - 20070082043 - Liposomal vaccine The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity. ... 04/12/07 - 20070082042 - Multiple-layered liposome and preparation method thereof Disclosed are multilayered liposomes for transdermal absorption and a method of preparing the liposomes. The multilayered liposomes are prepared using a mixture of oil-phase components comprising squalane, sterols, ceramides, neutral lipids or oils, fatty acids and lecithins, is 200 to 5000 nm in particle size, and is capable of entrapping ... 04/05/07 - 20070077292 - Compositions and methods for improved skin care Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen. ... 04/05/07 - 20070077291 - Drug delivery nanocarriers targeted by landscape phage A targeted drug delivery nanocarrier and a method of forming the same is disclosed herein. The targeted drug delivery nanocarrier includes a plurality of amphipathic molecules forming a carrier particle having a plurality of drug molecules contained therein. A targeted landscape phage protein assembly is complexed to the carrier particle ... 04/05/07 - 20070077290 - High delivery rates for lipid based drug formulations, and methods of treatment thereof Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations. ... 04/05/07 - 20070077289 - Cream containing interferon encapsulated with liposome This invention relates to a cream containing interferon encapsulated with liposome, which comprises IFN liposome and cream substrate. The advantage of the cream of the present invention is high efficiency of encapsulation, stable production technique, good homogeneity of products, stable efficacy and low rate of leakage. In order to improve ... 03/29/07 - 20070071805 - Treatment of inflammation and vascular abnormalities of the eye Inflammation and vascular abnormalities of the eye, including those related to ischemia, its prophylaxis and its alleviation, are treated by administration to the mammal of small amounts of phosphate-glycerol group presenting bodies such as phosphatidylglycerol liposomes. ... 03/29/07 - 20070071804 - Compositions and methods of preparation of liposomal microparticulate il-12 This invention provides methods and compositions for localized delivery of IL-12 to a desired site. The composition comprises liposomes carrying IL-12. The liposomes comprise phosphatidyl choline, phosphatidyl glycerol and cholesterol. The size and composition of the liposomes is such that there is minimal leakage into the systemic circulation. These compositions ... 03/22/07 - 20070065499 - Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof The present invention provides methods of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprising (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; ... 03/22/07 - 20070065498 - Encapsulated arsenic drugs The present invention relates to methods and compositions for the treatment of cancer and for research and analysis of cancer. In particular, the present invention provides encapsulated arsenic anti-cancer compositions with improved properties. ... 03/22/07 - 20070065497 - Combination and method using edta combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-plate The invention is for the combination of EDTA and glutathione in the reduced state encapsulated in a liposome for prevention and therapy of coronary artery disease (CAD), and anti-thrombotic effect and for the effect of restoring platelet aggregation, an integral component of thrombus formation, to normal. The combination is particularly ... 03/15/07 - 20070059353 - Polyarginine-modified liposome having nuclear entry ability With the object of providing a liposome having cellular and nuclear entry ability, to achieve this object, a liposome is provided having on its surface a peptide comprising multiple consecutive arginine residues, and specifically a liposome is provided wherein the peptide is modified with a hydrophobic group or hydrophobic compound ... 03/15/07 - 20070059352 - Therapeutic liposomes The invention provides methods for correcting an imbalance of one or more entities in a mammal, as well as therapeutic liposomes and compositions for use with such methods. ... 03/08/07 - 20070053971 - Antimicrobial and antiviral compounds and methods for their use The present invention provides protonated compounds having antiviral and antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi. The invention also provides antiviral compositions comprising compounds of ... 03/08/07 - 20070053970 - Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to improve symptoms in disease states related to diminished function of the methylation pathway such as autism, other neurodegenerative diseases and abnormalities of neurotransmitter levels in ... 02/22/07 - 20070042032 - Self forming, thermodynamically stable liposomes and their applications Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents. ... 02/22/07 - 20070042031 - Systems and methods for manufacturing liposomes The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. A therapeutic agent, such as nucleic acid, ... 02/22/07 - 20070042030 - Preparation for the application of agents in mini-droplets The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers ... 02/22/07 - 20070042029 - Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (vegf-r) The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases ... 02/15/07 - 20070036848 - Estrogen compositions and therapeutic methods of use thereof A pharmaceutical composition comprises at least one estrogenic compound, the composition being adapted for application in a unit dose amount to a vulvovaginal surface and having at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface, wherein the at least ... 02/08/07 - 20070031484 - Immunoliposomes that optimize internationalization into target cells The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab′ domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides ... 02/08/07 - 20070031483 - Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates ... 02/08/07 - 20070031482 - Pdt treatment method for cellulites and cosmetic use A photosensitizer mixture and a method of treating cellulites by means of a percutaneous application of the mixture into the area of cellulite buildup followed by light illumination are presented. The photosensitizer can be combined with one or more cellular products including adipose cells and/or collagen that have been previously ... 02/08/07 - 20070031481 - Phospolipid derivative A phospholipid derivative represented by the following formula (I) wherein R1CO and R2CO independently represent an acyl group; R3 represents hydrogen atom, or a hydrocarbon group; symbol “a” represents an integer of 0 to 4; symbol “b” represents 0 or 1, provided that when a is 0, b is 0; ... 02/08/07 - 20070031480 - Enhanced delivery of sphingolipids Compositions which comprise delivery vehicles having stably associated therewith at least one organic acid derivative of a sterol are useful in achieving enhanced cellular delivery of physiologically relevant sphingolipids when the compositions are administered. ... 02/01/07 - 20070026061 - Liposomal formulation and use thereof Cationic liposome encapsulated antimonial drugs formulations are provided. The drug-loaded liposome have enhanced efficacy as antileismanial agents and provide improved therapeutic index as compared to the minimal dose of free drug. ... 02/01/07 - 20070026060 - Method for treating advanced ovarian cancer A method for treating advanced epithelial ovarian cancer patients who attain a clinically-defined complete response after initial platinum/paclitaxel-based chemotherapy is described. The method involves administering a chemotherapeutic agent, such as doxorubicin, entrapped in liposomes. ... 02/01/07 - 20070026059 - Ligands for orphan nuclear hormone receptor steroidogenic factor-1 (sf-1) The 1.5 Å crystal structure of the orphan nuclear receptor steroidogenic factor 1 (SF-1) ligand binding domain in complex with an LxxLL motif from a co-regulator protein is disclosed. The structure reveals the presence of a phospholipid ligand in a surprisingly large pocket (˜1600 Å3), with the receptor adopting the ... 02/01/07 - 20070026058 - Method and composition for treating rhinitis There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier. The compositions are preferably homogeneous in their nature. ... 02/01/07 - 20070026057 - In vivo targeting of dendritic cells The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the ... 01/25/07 - 20070020327 - Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare prostate cancer-associated antigen epitopes, and to develop epitope-based vaccines directed towards prostate tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention ... 01/25/07 - 20070020326 - Drug delivery system and method A method for delivering a therapeutic agent to a predetermined location in a host is disclosed, wherein a liposome-encapsulated therapeutic agent is administered to the host, and an electrical field which encompasses a predetermined region within the host is established, such that as the liposome-encapsulated agent is exposed to the ... 01/18/07 - 20070014845 - Liposomal delivery vehicle for hydrophobic drugs A liposome composition having a high drug concentration of a hydrophobic drug and capable of retaining the drug in entrapped form is described. The liposomes are comprised of high phase transition lipid and a lipopolymer, which together permit retention of a high concentration of a drug/cyclodextrin complex that achieves a ... 01/18/07 - 20070014844 - Method of treating patients with a mucinous glycoprotein (muc-1) vaccine The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation. ... 01/18/07 - 20070014843 - Sustained release enhanced lipolytic formulation for regional adipose tissue treatment Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments ... 01/18/07 - 20070014842 - Pharmaceutical liposomal compositions Pharmaceutical compositions comprising a liposome associated to N. meningitidis polypeptides fragments or analogs thereof or corresponding DNA fragments, can be used to prevent, diagnose and/or treat neisserial infections. ... 01/18/07 - 20070014841 - Pharmaceutical compositions The present invention relates to polypeptides, epitopes and antibodies directed to these epitopes, more particularly to the Sip polypeptide of Group B Streptococcus (GBS), also called Streptococcus agalactiae which may be used to prevent, diagnose and/or treat streptococcal infection. ... 01/18/07 - 20070014840 - Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can ... 01/04/07 - 20070003610 - Application of lipid vehicles and use for drug delivery The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to ... 01/04/07 - 20070003609 - Vectorization of dsrna by cationic particles and topical use The present invention relates to vectorization of double stranded RNA oligonucleotides by cationic particles chosen from among surfactant micelles, block or non-block polymer micelles, cationic liposomes and niosomes, cationic oleosomes and cationic nanoemulsions, as well as from among cationic organic or inorganic particles and nanocapsules, and topical compositions for the ... 01/04/07 - 20070003608 - Compounds, compositions and methods for the treatment of viral infections and other medical disorders The present application provides methods and compositions for improving the bioavailability of a lipid-containing antiviral compound, and in particular, an antiviral lipid-containing compound. In one embodiment, pharmaceutically acceptable compositions are provided that include an antiviral lipid-containing compound, or salt, ester, or prodrug thereof and one or more bioavailability enhancing compounds, ... 01/04/07 - 20070003607 - Neutral liposome-encapsulated compounds and methods of making and using thereof The disclosed matter relates to neutral liposomes containing an encapsulated compound and post-insertion compound. Also described herein are methods of making and using the neutral liposomes. ... 12/28/06 - 20060292211 - Ultrasound enhancement of drug release across non-ionic surfactant membranes A method of targeted drug delivery and imaging using nonionic surfactant vesicles (niosomes) in combination with ultrasound. Niosomes have potential applications in targeted drug delivery and imaging because of their ability to encapsulate therapeutic agents and their enhanced uptake by physiological membranes. Ultrasound may be used to mediate delivery non-invasively ... 12/21/06 - 20060286161 - Injectable liposomal depots for delivering active ingredients The invention relates to liposomal formulations for the production of an injectable depot of peptide, protein and oligonucleotide active substances for sustained release and effect in a mammal body. ... 12/14/06 - 20060280786 - Pharmaceutical formulations for minimizing drug-drug interactions A pharmaceutical combination for minimizing pharmacokinetic drug-drug interaction is described including a first pharmaceutical component having a particular pharmacokinetic profile in a mammal and a second pharmaceutical component formulated for parenteral administration having an altered pharmacokinetic profile different from the unaltered pharmacokinetic profile of the second pharmaceutical component, which would ... 12/14/06 - 20060280785 - Biocidal materials for treatment against pathogens Applicant's present invention is a biocidal material for in vivo use for treatment of pathogenic infections comprising nanoparticles or nanostructures of biocidal material encapsulated within a liposomal carrier. ... 12/14/06 - 20060280784 - Compound modified with glycerol derivative directly or via the spacer, or a salt thereof; a fine particle comprising the same; and the like. ... 12/07/06 - 20060275356 - Pharmaceutical compositions for treating or preventing coronary artery disease The present invention provides pharmaceutical compositions and methods for raising plasma levels of apolipoprotein A-I in a mammal, e.g. for treating or preventing coronary artery disease (CAD). The inventive pharmaceutical compositions comprise: (a) a negatively charged phospholipid; and (b) at least one intestinal absorption enhancer; where (a) and (b) are ... 12/07/06 - 20060275355 - Processed water and therapeutic uses thereof A physiologically ingestible composition of matter obtained by using super-oxygenated water, and the uses thereof, are provided. The obtaining method includes combining water with first oxygen, and manipulating the combined water and first oxygen into a vortex so as to cause the first oxygen to diffuse into the water and ... 11/30/06 - 20060269595 - Liposomal antineoplastic drugs and uses thereof This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent. ... 11/30/06 - 20060269594 - Liposomal antineoplastic drugs and uses thereof This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent. ... 11/30/06 - 20060269593 - Adjuvant for transcutaneous immunization A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and/or cellular effectors) after transcutaneous application of a formulation ... 11/23/06 - 20060263422 - Pharmaceutical composition containing decoy and use of the same A pharmaceutical composition is provided for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or ... 11/16/06 - 20060257466 - Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis Macrophage targeting formulations of compounds for treating atherosclerosis, in particular compounds which modulate cholesterol-metabolizing enzymes including, but not limited to acyl CoA:cholesterol acyl transferase (ACAT) inhibitors, cholesterol ester hydrolase (CEH) enhancers and combinations thereof, are provided. Methods for short term administration of these macrophage targeting formulations to promote regression and/or ... 11/16/06 - 20060257465 - Methods for preparation of lipid-encapsulated therapeutic agents Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize ... 11/16/06 - 20060257464 - Transfection reagents The present invention provides optimized transfection reagents comprising mixtures of cationiclipoids. In particular, the present invention provides DNA delivery vehicles based on identifying the optimal hydrophobicity of novel cationic phospholipid derivatives that, alone or in combination, form complexes with DNA (lipoplexes) and exhibit enhanced transfection activity. ... 11/09/06 - 20060251712 - Method and composition for hyperthermally treating cells A method for the hyperthermia treatment of tissue in a target site applies a heat source to kill cells without protein denaturization. The method introduces an encapsulated dye that is released at a selected temperature in the target site to indicate that a threshold temperature has been reached to hyperthermally ... 11/09/06 - 20060251711 - Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal This invention relates to a sterically stabilized liposome carrier effective for the delivery of treatment to a mammal in a composition comprising a sterically stabilized liposome and a drug effective for the treatment of a mammal with the composition as an aerosol with the composition providing effective treatment for a ... 11/09/06 - 20060251710 - Micelle composition of polymer and passenger drug Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and/or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic ... 11/09/06 - 20060251709 - Artificial lipid bilayer double-membrane forming device and artificial lipid double-membrane forming method of utilizing the same An artificial lipid bilayer membrane formation device is disclosed. It includes: an upper solution chamber whose bottom has a small hole; a lower solution chamber having a support layer; and lipid solution exclusion device. Lipid solution is applied to the small hole, and the lipid solution exclusion device excludes surplus ... 11/09/06 - 20060251708 - Coenzyme q10 containing proliposome and preparation thereof A coenzyme Q10 and ceramide-containing preliposome, and pharmaceutical preparations and cosmetics containing the same. The preliposome can further comprise other lipid components. A granular and lyophilized solid-preparation is produced by lyophilization or spray drying. Then, the coenzyme Q10-containing proliposome is obtained by adding water in the said solid-preparation and shaking. ... 11/02/06 - 20060246126 - Therapeutic liposome composition and method of preparation Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, ... 11/02/06 - 20060246125 - Human mitochondrial proteins and polynucleotide encoding the proteins The invention of the present application provides an isolated and purified human mitochondrial protein comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, which is a novel human protein promoting aggregation and fusion of mitochondria. The present invention also provides a polynucleotide encoding such ... 11/02/06 - 20060246124 - Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally The present invention relates to a method of treating cancer in a patient comprising administering to the patient intraperitoneally, a cancer treating effective amount of a lipid-based platinum compound formulation. ... 11/02/06 - 20060246123 - Oligonucleotide mimetics The present invention relates, in general, to a method of using aptamers to modulate the immune system and, in method of inhibiting CTLR-4 function and to aptamers suitable for use in such a method. ... 10/26/06 - 20060240093 - Lipid encapsulated interfering rna The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell. ... 10/26/06 - 20060240092 - Polymeric micelles for drug delivery The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. ... 10/26/06 - 20060240091 - Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof A novel targeting peptide from the C-terminal of endothelin and/or a novel fusogenic peptide from hemagglutinin are optionally conjugated to the carboxy group of 1,2-dioleoyl-sn-glycero-3-succinate and incorporated into liposomes for therapeutic treatment. The novel targeting peptide directs liposomes to lung cells, and, therefore, is useful for delivering liposomes encapsulating cholinesterase ... 10/26/06 - 20060240090 - Combination compositions of camptothecins and fluoropyrimidines Compositions which comprise liposomes having stably associated therewith a camptothecin and a fluoropyrimidine are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered. ... 10/26/06 - 20060240089 - Use of pvp-iodine liposomes for treatment of herpes The invention concerns a method for the production of a pharmaceutical preparation for the treatment of Herpes forms that is characterized in, that the preparation comprises at least one anti-septic compound associated with a particular carrier. ... 10/26/06 - 20060240088 - Caged ligands and uses thereof Provided are caged compounds comprising a ligand that specifically reacts with a receptor not naturally present in mammals. The cage is released from the ligand upon illumination of the compound with light. Also provided are cells transfected with a gene of interest and a gene encoding a receptor, the gene ... 10/12/06 - 20060228407 - Enhanced delivery via serpin enzyme complex receptor Serpin enzyme complex receptors are used as targets for therapeutic drugs in the lungs and brain tissue. any lung or brain disease and any therapeutic drug can be targeted to the lung or brain by use of ligands which specifically bind to the receptors. Complexes for delivery may include proteins, ... 10/12/06 - 20060228406 - Transfection reagent for non-adherent suspension cells The present invention discloses liposomal transfection reagents for delivery of macromolecules and other compounds into cells, particularly non-adherent suspension cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed. ... 10/12/06 - 20060228405 - Phospholipid-based pharmaceutical formulations and methods for producing and using same Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid ... 10/12/06 - 20060228404 - Compositions and methods for treatment of hypertrophic tissues The present invention provides compositions and methods for treatment of conditions and diseases associated with excessive or inappropriate noncancerous tissue growth. In certain embodiments of the invention the compositions and methods are used for treatment of benign prostatic hyperplasia. In certain embodiments of the invention the composition comprises a tissue-selective ... 10/12/06 - 20060228403 - Nutritional supplements for cardiovascular health An admixture containing as active ingredients omega-3 polyunsaturated fatty acids selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linoleic acid (LNA), curcumin, B complex vitamins selected from folic acid, B6 and B12, antioxidant vitamins selected as vitamin C and vitamin E and ubiquinone. This compound is being designed for ... 10/12/06 - 20060228402 - Techniques for forming a lipid bilayer membrane A method for forming a lipid bilayer membrane is provided, the method comprising forming a layer of lipid molecules on a liquid surface at an air-liquid interface between a liquid volume and an air volume. An aperture is moved from the liquid volume to the air volume through the layer ... 10/05/06 - 20060222698 - Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free glargine insulin and glargine insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Glargine insulin is present within the complex in ... 10/05/06 - 20060222697 - Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the ... 10/05/06 - 20060222696 - Novel liposome compositions The present disclosure provides lipid-containing compositions, including targeted liposomes encapsulating drug, and pharmaceutical formulations thereof, as well as methods for the making and using the lipid-containing compositions, including the use of the targeted liposomes in the treatment of cancer and other diseases. ... 10/05/06 - 20060222695 - Deoxycholic acid liposome-based dermatological topical preparation A dermatological topical preparation such a cream, a lotion, an emulsion, a paste, an ointment and the likes including liposomes carrying lipo-dissolving substances encapsulated by the liposomes wall or incorporated with the liposomes wall components. The lipo-dissolving substance is released by the liposomes into the target adipose tissue or its ... 10/05/06 - 20060222694 - Stabilized topotecan liposomal composition and methods A topotecan liposomal composition which can be reconstituted from a lyophilized form to an injectable liposome suspension having selected liposome sizes in the size range between 0.05 and 0.25 microns, and between about 85-100% liposome-entrapped topotecan is disclosed. ... 09/28/06 - 20060216343 - Pharmaceutical compositions comprising an oligonucleotide as an active agent A pharmaceutical composition is disclosed, which composition comprises an oligonucleotide as an active agent, the oligonucleotide being adapted to target nucleic acids encoding CD40 thereby to modulate the expression of CD40 in mammalian cells, and a liposome as an excipient. Said liposome is an amphoteric liposome. Also disclosed is a ... 09/28/06 - 20060216342 - Micelle delivery system loaded with a pharmaceutical agent The invention is directed to an improved drug delivery system that includes a micelle, comprising polyethylene glycol and a lipid component, and a pharmaceutical agent dispersed in the lipid component. The delivery system may also include a targeting ligand. The micelle delivery system of the invention is capable of stabilizing, ... 09/28/06 - 20060216341 - Compositions for treating drug resistance Delivery vehicle compositions having stably associated therewith at least one therapeutic agent and at least one drug resistance modulator are useful in achieving a biologic effect to a drug resistance target. ... 09/21/06 - 20060210619 - Limposomes containing asiaticoside and the uses thereof This invention belongs to the chemical field, which is related to the fields of pharmaceutical preparations and cosmetic, especially to asiaticoside-liposome and its use for preparing pharmaceutical preparations and cosmetic. In this invention, asiaticoside and lipid components are fused by heating or dissolved in organic solvents, then treated with the ... 09/21/06 - 20060210618 - Phospholipid derivatives and process for the production there wherein [PG]k represents a residue of polyglycerin having a polymerization degree of k, wherein k is 2 to 50, R1CO and R2CO independently represent an acyl group having 8 to 22 carbon atoms, symbol “a” independently represents an integer of 0 to 5, symbol “b” independently represents 0 or 1, ... 09/14/06 - 20060204566 - Novel liposome complexes for increased systemic delivery Highly efficient cationic liposomes have been developed as an improved delivery system for biologically-active reagents. A novel structure, the sandwich liposome, is formed and comprises one or more biologically active agents internalized between two bilomellar liposomes. This structure protects the incoming agent and accounts for the high efficiency of in ... 09/14/06 - 20060204565 - Conjugates and use thereof where the group L comprises a vitamin, or a vitamin-receptor binding analog or derivative thereof, and the group X comprises an immunogen, a cytotoxin, or another compound capable of altering macrophage function. ... 09/07/06 - 20060198882 - Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer The present invention concerns a stable lipid assembly comprising a biologically active lipid having a hydrophobic region and a polar headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is less than 0.3, and a lipopolymer having a hydrophobic lipid region and a polymer headgroup, wherein the ... 08/31/06 - 20060193906 - Sugar-modified liposome and products comprising the liposome The present invention provides a sugar-modified liposome having a sugar chain bonded to its membrane surface, preferably through a linker protein, and having excellent absorption qualities, particularly in the intestine. The molecular structure and quantity of the sugar chain is selectively varied to allow the liposome to be delivered in ... 08/31/06 - 20060193905 - Direct cellular energy delivery system A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a ... 08/31/06 - 20060193904 - Liposome loading with metal ions This invention relates to encapsulation of drugs and other agents into liposomes. ... 08/31/06 - 20060193903 - Glycoside-containing liposome A drug product which can maximize the effect of a cholestanol glycoside useful as an anticancer agent. The present invention provides a liposomal composition containing a glycoside exhibiting antitumor activity, a phospholipid, and a positive-charge-providing substance; the glycoside being composed of GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, or Gal- as a sugar ... 08/31/06 - 20060193902 - Pharmaceutical compositions containing active agents having a lactone group and transition metal ions Compositions and methods for stabilizing an active agent containing one or more actone rings. The compositions, including pharmaceutical compositions, ensure that the lactone ring of the active agent is stabilized in the active, ring-closed form due to the inclusion of a transition metal ion. ... 08/24/06 - 20060188562 - Materials and methods for drug delivery and uptake The subject invention pertains to novel materials and methods for use in delivering and sequestering substances, such as pharmacological agents, within a patient. One aspect of the invention is directed towards core-shell particles having a core encapsulated within a calcium carbonate shell, with an intermediate layer composed of an amphiphilic ... 08/24/06 - 20060188561 - Pharmaceutical compositions for lipophilic drugs Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms ... 08/24/06 - 20060188560 - Delivery system for nucleic acids αvβ3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic αvβ3 integrin antagonist. ... 08/24/06 - 20060188559 - Topical cosmetic compositions comprising alpha arbutin This invention is a topical tyrosinase inhibiting combination using alpha arbutin and bearberry extract, in synergism, for the purpose of skin lightening. The active admixture is a dermatological serum comprised of alpha arbutin, octyl stearate and polyolprepolymer-2, introduced onto the human skin in liposome form for ultra-deep penetration. ... 08/17/06 - 20060182795 - Compositions containing inclusion complexes The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used ... 08/17/06 - 20060182794 - Stabilized compositions for topical administration and methods of making same A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition preferably comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as ... 08/17/06 - 20060182793 - Cpg-packaged liposomes Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFNα in vivo. These findings are relevant ... 08/17/06 - 20060182792 - Liposome-forming compositions The invention relates to liposome-forming compositions, liposomes produced therewith and the use of said liposome-forming compositions in the production of liposomes. ... 08/10/06 - 20060177495 - Polymer-lipid delivery vehicles Delivery vehicles comprising nanoparticles which are composed of: (a) a biodegradable hydrophobic polymer forming a core, and; (b) an outer amphiphilic layer surrounding the polymer core containing a stabilizing lipid are suitable for delivering active agents. ... 08/03/06 - 20060172003 - Modular targeted liposomal delivery system A liposome including a fusogenic liposome, a linking moiety and a targeting moiety. The fusogenic liposome is a lipid bilayer encapsulating contents. The linking moiety is electrostatically bound to the lipid bilayer, and the targeting moiety is covalently bound to the linking moiety. The liposome may also include a stabilizing ... 07/27/06 - 20060165773 - Gene therapy of tumors using non-viral delivery system The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and ... 07/27/06 - 20060165772 - Combretastatin a-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4. ... 07/27/06 - 20060165771 - Compositions for delivery of drug combinations Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered. ... 07/27/06 - 20060165770 - Lipid particles having asymmetric lipid coating and method of preparing same A method of preparing lipid particles having an asymmetric lipid coating is described. The lipid composition of the outer lipid coating of the particles varies from the inner to outer surfaces. The asymmetric lipid particles are formed by preparing a lipid composition containing a charged lipid and a therapeutic agent, ... 07/27/06 - 20060165769 - Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations Compounds and compositions are disclosed for increasing the bioavailability of lipophilic drugs, and more specifically, to solubilizing lipophilic drugs using bioenhancers that cause no efflux inhibition or a desired degree of efflux inhibition. Methods of making and using such compositions are also disclosed. ... 07/27/06 - 20060165768 - Novel lipophilic compounds and uses thereof e) X− is an anion. ... 07/27/06 - 20060165767 - Thermolabile liposome with a controlled release temperature The invention relates to a thermolabile liposome with a controlled release temperature for the liposome content, in particular a liposome which is stable at 37° C. in serum and with a controlled release temperature of between 40 and 80° C. ... 07/27/06 - 20060165766 - Method for preparing liposome formulations with a predefined release profile The present invention provides a novel tool for designing a release profile of an active agent from a liposome in to which it is loaded. According to the invention, a method is provided for preparing a liposomal formulation for delivery of an active agent to a target, the release of ... 07/20/06 - 20060159740 - Hydrophobic photosensitizer formulations for photodynamic therapy Pharmaceutical liposomal formulations for photodynamic therapy are presented, which are stable in storage as liquid formulations, comprise a hydrophobic photosensitizer and one or more synthetic phospholipids. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. The formed liposomes contain the hydrophobic photosensitizer within the lipid bilayer ... 07/20/06 - 20060159739 - Liposomes containing an entrapped compound in supersaturated solution A liposome composition having a compound entrapped in a supersaturated solution and method for preparing such a composition are described. ... 07/20/06 - 20060159738 - Cationic liposomes and methods of use Highly efficient cationic liposomes are provided as a system for the delivery to cells of agents or compounds, such as, compounds capable of silencing a target protein and enzyme stubstrates. The cationic liposomes can be used in methods of detecting the inhibition activity or apparent activity of a target protein ... 07/20/06 - 20060159737 - Pharmaceutical compositions for local administration A pharmaceutical composition for local application is disclosed, said composition comprising a nucleic acid as a therapeutic agent, an excipient and a pharmaceutically acceptable vehicle therefor, said excipient comprising a liposome. The excipient comprises an amphoteric liposome having an isoelectric point between 4 and 7.4 and said composition is formulated ... 07/20/06 - 20060159736 - Liposome formulations of boronic acid compounds A liposome composition comprised of liposomes having the peptide boronic acid proteasome inhibitor compound bortezomib entrapped in the liposomes is described. The boronic acid compound is entrapped in the liposomes in the form of a boronate ester, subsequent to interaction with a liposome-entrapped polyol. In one embodiment, the liposomes have ... 07/20/06 - 20060159735 - Method of reclaiming drug compound from liposomal drug manufacturing stream from a feedstock solution of the compound, comprises the steps of assaying a permeate wash for HSPC and cholesterol; processing the permeate wash to form a concentrated solution of the compound if the assay result is lower or equal to a predetermined value; and adding the concentrated solution to the ... 07/13/06 - 20060153907 - Liposome formulations of boronic acid compounds A liposome composition comprised of liposomes having a peptide boronic acid proteasome inhibitor compound entrapped in the liposomes is described. The boronic acid compound is entrapped in the liposomes in the form of a boronate ester, subsequent to interaction with a liposome-entrapped polyol. In one embodiment, the liposomes have an ... 07/13/06 - 20060153906 - Pharmaceutical product for endonasal administration for treating central nervous system disease and disorders The invention concerns a pharmaceutical product consisting of one or more standard active substances and/or of one or more standard metabolites acting on the central nervous system. Said active substances are added with substances acting on the nasal mucous membrane for endonasal administration. ... 07/06/06 - 20060147514 - Method for introducing antisense oligonucleotides into eucaryotic cells The present invention relates to a method for introducing one or more antisense oligonucleotides into one or more eucaryotic cells using one or more lipid formulations comprising one or more cationic lipids of Formula I and optionally at least one neutral lipid. In particular, the present invention relates to a ... 07/06/06 - 20060147513 - Methods of forming targeted liposomes loaded with a therapeutic agent The present invention provides for liposomes loaded with a therapeutic agent, which liposomes are targeted to a cell of interest by incubation with a targeting protein protein conjugated to a linker molecule comprising a hydrophobic domain, a hydrophilic polymer chain terminally attached to the hydrophobic domain, and a chemical group ... 07/06/06 - 20060147512 - Compositions and methods of use for treatment of mammalian diseases This disclosure relates to a Composition having medicinal properties for use with mammalian diseases such as anti-cancer properties and methods of use, anti-viral properties and methods of use, anti-protozoan properties and methods of use, and anti-bacterial properties and methods of use in mammals. A chemical Composition for use as a ... 07/06/06 - 20060147511 - Liposomal glucocorticoids The invention relates to a liposomal formulation comprising water-soluble glucocorticoids, to the use of said formulation in the treatment of inflammatory diseases, and to a kit comprising said liposomal formulation, e.g. in the form of a pharmaceutical agent. ... 06/29/06 - 20060141021 - Polymeric microspheres and method for preparing the same A polymeric microsphere. The polymeric microsphere comprises a first polymer, a layer formed on the surface of the first polymer, and a second polymer formed on the layer. The invention also provides a method for preparing the polymeric microphere by an aqueous-two-phase emulsion process. ... 06/29/06 - 20060141020 - Liposomes containing oligonucleotides It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5′-GTGCTCCATTGATGC-3′ (SEQ. ID. NO: 1) wherein only the end bases are phosphorothioated is a preferred embodiment. Antisense sequences of up to 40 bases which contain this sequence, such as 5′-CCTGTATGTGCTCCATTGATGCAGC-3′ (SEQ ... 06/29/06 - 20060141019 - Liposome The present invention provides a liposome to which a polyalkylene glycol and albumin are bonded having an excellent retention in blood. ... 06/22/06 - 20060134189 - Sirna silencing of apolipoprotein b The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence ApoB expression and methods of using such nucleic acid-lipid particles to silence ApoB expression. ... 06/15/06 - 20060127471 - Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy Pharmaceutical pegylated liposomal formulations for photodynamic therapy are presented. The pegylated liposomal formulation provides therapeutically effective amounts of the photosensitizer for intravenous administration. At least one of the phospholipids in the liposomes has been linked with poly ethylene glycol (PEG) as an integral part of the phospholipids. The formed pegylated ... 06/15/06 - 20060127470 - Use of buckysome or carbon nanotube for drug delivery Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and ... 06/15/06 - 20060127469 - Methods of delivering stable topical drug compositions A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature. ... 06/15/06 - 20060127468 - Methods and related compositions for reduction of fat and skin tightening Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent ... 06/15/06 - 20060127467 - Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods The present invention relates to lipid based nanoparticles or liposomes that are sensitive to ultrasonic energy, compositions containing these particles, methods for delivering one or more active agents using the particles, and methods for preparing the particles. The nanoparticles and liposomes encapsulate active agents such as chemotoxins, genes, virus vectors, ... 06/15/06 - 20060127466 - Method for transdermal or intradermal delivery of molecules The present invention provides a method for transdermal delivery of molecules. The method comprises the application of electrical pulses concurrently or sequentially with application of the molecules and a lipid composition comprising negatively charged liposomal compositions. The application of the liposomal components enhances permeability of the target site for delivery ... 06/08/06 - 20060121105 - Method of lipid structure preparation A method of inserting a lipid-linked moiety into a lipid assembly, such as a planar lipid monolayer or bilayer, a spherical lipid vesicle, a micelle, or an emulsion envelope monolayer is described. In the method, the lipid assembly and the lipid-linked moiety are contacted in the presence of microwave irradiation ... 06/01/06 - 20060115523 - Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal This invention relates to a composition containing a sterically stabilized liposome and triamcinolone, effective for the treatment of a mammal, with the composition being adapted for administration as an aerosol and with the composition providing effective treatment for a period of time at least 1.5 times as long as the ... 05/25/06 - 20060110441 - Lyophilized liposome formulations and method Formulations and methods for preparing a lyophilized composition comprising liposomes comprised of an unsaturated lipid and a hydrophobic drug associated with the liposome, and a cryoprotectant in a solution at a selected concentration. The phase transition temperature of the lipid is greater than the freezing point of the solution at ... 05/25/06 - 20060110440 - Method and system for biasing cellular development Compositions and methods comprising siRNA targeted to APP mRNA are advantageously used to transfect stem cells and bias the cells against differentiating into glial type neural cells. The siRNA of the invention causes RNAi-mediated silencing of the APP mRNA. The inventors have discovered that expression APP induces gliogenesis, i.e., promotes ... 05/25/06 - 20060110439 - Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds The present invention relates to methods and compositions for the treatment of skin-related conditions and disorders. In one aspect, the invention features methods and compositions for the transdermal delivery of compounds for the treatment of skin-related conditions and disorders, wherein the compositions include meglumine and a liposome component. ... 05/25/06 - 20060110438 - Liposome stabilizing agent [wherein M represents a hydrogen atom or a monovalent cation and m, which defines the methylene chain length, represents an integer of 1 to 5], and the other two each represent an chain hydrocarbon group, A1, A2 and A3 are each independently selected from the group consisting of C(O)O, CONH ... 05/25/06 - 20060110437 - Synthesis and self-assembly of abc triblock bola peptide The present invention provides for bola amphiphiles compositions which have more than one lyophilic (hydrophilic) head group and a hydrophobic (hydrophobic) moiety capable of hydrogen bonding with other bola amphiphiles. These bola amphiphiles are capable of self assembling into micelles. The advantage of these bola amphiphiles is that they may ... 05/25/06 - 20060110436 - Phospholipid derivative A phospholipid derivative, utilizable for modification of liposomes and the like, which is a copolymer containing, as essential component units, a component unit A represented by the formula (1), a component unit B represented by the formula (2A) and/or the formula (2B), and a component unit C represented by the ... 05/25/06 - 20060110435 - Allergy vaccine composition, production method thereof and use of same in allergy treatment The present invention relates to the field of Immunology, specifically with the branch of Immuno-Allergy and in particular with the use of adjuvant or carrier compounds, capable of modulating the immune response to allergens. The technical objective that is pursued is to obtain a pharmaceutical preparation of therapeutic or prophylactic ... 05/18/06 - 20060105032 - Multiple sclerosis treatment Symptoms, including biochemical correlates, of multiple sclerosis (MS) in a mammal are beneficially affected by administering to the mammal small doses of bodies, such as liposomes, of a size resembling that of mammalian cells, the bodies having phosphate glycerol head groups presented exteriorly on their surfaces. Preferred are liposomes comprised ... 05/18/06 - 20060105031 - Accelerating recovery from trauma Mammalian patients suffering from physical trauma, or about to likely suffer such trauma (by surgical treatment, or by suffering unanticipated accidental injuries, battle injuries or the like) are treated to lessen the severity of or accelerate the recovery from such consequently sustained trauma, by administering to the patient immune system-modifying ... 05/11/06 - 20060099244 - Liposomal formulation for oral administration of glutathione (reduced) The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related ... 05/11/06 - 20060099243 - Liposome drug delivery The invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration. ... 05/04/06 - 20060093662 - Liposomal camptothecins and uses thereof This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis. ... 05/04/06 - 20060093661 - Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system. ... 05/04/06 - 20060093660 - Compositions for treatment with glucagon-like peptide, and methods of making and using the same In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1. ... 04/27/06 - 20060088584 - Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy Pharmaceutical liposomal formulations are described for photodynamic therapy comprising a, hydrophobic porphyrin photosensitizer, a monosaccharide and one or more synthetic phospholipids, which are stable in storage especially through freeze-drying process. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. In particular derivatives of chlorins and bacteriochlorins, ... 04/27/06 - 20060088583 - Artificial oxygen carrier containing preventive agents of methb formation The present invention provides an agent containing L-tyrosine that prevents methemoglobin formation, and a vesicle comprising the above agent for preventing methemoglobin formation. More specifically, the present invention provides an oxygen infusion preparation suitable for long-term storage, which prevents an increase in methemoglobin content as a result of oxidation of ... 04/27/06 - 20060088582 - Phosphatidyl oligo glycerins and structural analogs This invention relates to novel structural analogs to phosphatidyl oligo glycerins. These compounds can be used, in particular, for producing liposomes having a long circulation time with or without thermolability. The invention also relates to liposomes containing compounds of the aforementioned type and to medicament compositions. ... 04/20/06 - 20060083782 - Methods and compositions useful for administration of chemotherapeutic agents In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material. ... 04/20/06 - 20060083781 - Functionalized solid lipid nanoparticles and methods of making and using same In one aspect, the invention relates to functionalized solid lipid nanoparticles comprising a neutral lipid and a first functionalized polymer comprising at least one ionic or ionizable moiety and methods for providing same. In a further aspect, the invention relates to tumor targeting therapeutic systems, multimodal diagnostic therapeutic systems, thermoresponsive ... 04/20/06 - 20060083780 - Cationic lipids and methods of use The present invention provides compositions comprising cationic lipids, liposomes and nucleic acid-lipid particles comprising the cationic lipids, and methods of using such compositions, liposomes, and nucleic acid-lipid particles. ... 04/13/06 - 20060078607 - Liposome formulation of 6,9-bis[(2-aminoethyl)-amino]benzo[g]isoquinoline-5, 10-dione dimaleate A liposome pharmaceutical formulation of the compound of 6,9-bis-[(2-aminoethyl)-amino]benzo[g]isoquinoline-5,10-dione dimaleate, the method for the preparation and the use thereof. ... 04/13/06 - 20060078606 - Sustained-release liposomal anesthetic compositions The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site ... 04/13/06 - 20060078605 - Pharmaceutical composition of small-sized liposomes and method of preparation A pharmaceutical composition of small sized unilamellar liposomes for the supply active principles by injection, with an improved permanency in the blood flow, where the unilamellar membrane contains a mixture of saturated lipids encompassing at least one lysophospholipid in a quantity from about 0.5 mol % to about 6.0 mol ... 04/06/06 - 20060073199 - Surfactant systems for delivery of organic compounds Submicron particles of an organic compound, such as therapeutic and diagnostic agent are disclosed. The organic compound particles are associated with at least two surfactants including a block copolymer and phospholipids conjugated with a hydrophilic polymer. ... 04/06/06 - 20060073198 - Sustained release of antifectives Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided ... 04/06/06 - 20060073197 - Encapsulated transfer factor compositions and methods of use Compositions comprising transfer factor and/or glucan, such as hybrid glucan, coated with a hydrophobic or lipid coating. The composition can be combined with nutraceuticals including zinc, essential fatty acids, lactic acid generating bacteria, etc. Also provided are methods for prevention and treatment of animal pathologies using these compositions as well ... 04/06/06 - 20060073196 - Use of p-glycoprotein inhibitor surfactants at the surface of a colloidal carrier Use of a colloidal carrier for the manufacture of a medicament for inhibiting P-glycoprotein, wherein said colloidal carrier:—encapsulates or adsorbs a pharmacologically active substance, and—comprises P-glycoprotein inhibitor surfactants bound to the colloidal carrier surface. ... 03/30/06 - 20060067998 - Liposomal curcumin for treatment of cancer The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery ... 03/30/06 - 20060067997 - Phospholipid complexes of lexitropsins, their preparation and use in therapeutic formulations Pharmaceutical formulations constituted by a lexitropsin phospholipidic complex in the form of liposomes, micelles or nanoparticles exhibit optimal pharmacological properties in respect to other formulations containing active principles belonging to the same chemical class in both the topical or parenteral treatment of infectious and/or tumour diseases. ... 03/23/06 - 20060062842 - Method of administering a compound to multi-drug resistant cells A composition for administration of a therapeutic compound to a multi-drug resistant cell in a person suffering from a drug-resistant cancer is described. The composition is composed of a carrier molecule and a folate targeting ligand, which is covalently attached to the carrier, and the therapeutic compound. In one preferred ... 03/23/06 - 20060062841 - Liposomal vectors The present invention provides for liposomal vectors which inhibit inflammation and/or enhance expression of transferred genes. It is based, at least in part, of the discovery that vectors comprising a nucleic acid carrying a gene of interest and a cationic liposome containing an immunosuppressive agent induce lower levels of inflammatory ... 03/23/06 - 20060062840 - Lipid microtubules with contolled bilayer numbers The wall thickness of lipid microtubules are controlled by selecting a methanol/water system and determining the required amount of a lipid to form the desired wall thickness. The lipid is dissolved in a small portion of the heated methanol and that clear solution is added to the remaining amount of ... 03/23/06 - 20060062839 - Efficient liposomal encapsulation under mild conditions A method for preparing liposomes containing at least one biologically active substance encapsulated therein under mild conditions comprises the following steps: (A) providing liposomes, wherein the liposomes are prepared by a method other than the instant method; (B) mixing the product of step (A) with a water-miscible organic solvent to ... 03/16/06 - 20060057194 - Cationic liposomes for gene transfer The present invention relates to synthetic cationic lipids, liposome formulations and the use of such compounds to introduce functional bioactive agents into cultured cells. ... 03/16/06 - 20060057193 - Delivery system for pharmaceutical agents The present invention relates to a delivery system for pharmaceutical agents. Said delivery system comprises liposomes which comprise in their internal compartment a pharmaceutical agent to be delivered and which have linked to their external surface the cell adhesion molecule NCAM or a fragment thereof. In a preferred embodiment said ... 03/16/06 - 20060057192 - Localized non-invasive biological modulation system The present invention provides methods for non-invasive localized delivery of biologically active molecules, comprising packaging a molecule(s) of interest inside a thermosensitive particle, administering said particles to a subject, and inducing localized release of said molecules from said particles using a focused heat source. The thermosensitive particles may be thermosensitive ... 03/09/06 - 20060051407 - Method of treating ischemia-reperfusion injury The present invention relates to methods and compositions designed for the prevention, reduction, treatment or management of ischemia-reperfusion injury. The methods of the invention comprise the administration of an effective amount of a therapeutic formulation containing one or more active compounds in a formulation which specifically decreases or inhibits the ... 03/09/06 - 20060051406 - Formulation of insoluble small molecule therapeutics in lipid-based carriers The present invention provides formulations containing at least one unsaturated amphiphilic lipid and an amphipathic or hydrophobic drug and methods of making these formulations. In particular, the present invention provides formulations of least one unsaturated phospholipid and an amphipathic or hydrophobic pyrimidine drug, methods of making these formulations and the ... 03/09/06 - 20060051405 - Compositions for the delivery of therapeutic agents and uses thereof The present invention provides drug delivery vehicles comprising polytheylyene-lipid conjugates (PEG-lipid), wherein the circulation lifetime and biodistribution of the drug delivery vehicles are regulated by the PEG-lipid. More particularly, the present invention provides liposomes, SNALP and SPLP comprising such PEG-lipid conjugates, and methods of using such compositions to selectively target ... 03/02/06 - 20060045910 - Preserved fusogenic vesicles Preserved fusogenic vesicles are disclosed that include a saccharide, a fusogen, and a first polar phospholipid that is a stable vesicle former. The preserved fusogenic vesicles have a fusion rate of at least 20 vesicle fusions per second when re-hydrated. Methods of preserving fusogenic vesicles also are disclosed. Unexpectedly, after ... 02/23/06 - 20060039965 - Drug delivery system for hydrophobic drugs Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions ... 02/23/06 - 20060039964 - Micelle assemblies The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. Also, the invention encompasses compounds of the formula: A-X-Y-Z-R1 wherein A is a carboxy group or is absent; X is a polyol, Y is —C(═O)—, —C(═S)—, or is absent; Z is O, ... 02/23/06 - 20060039963 - Lipid-analogo phosphoric acid triesters The present invention relates to novel phosphoric triesters which comprise apolar lipid structures. ... 02/23/06 - 20060039962 - Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine derivative, and at least one hydrogen-bonding group located either within said headgroup and/or in close ... 02/16/06 - 20060034909 - Protein and peptide delivery to mammalian cells in vitro Compositions and methods for delivery of proteins and peptides to mammalian cells in vitro are described. Specifically, polypeptide-surfactant complexes formed from noncovalent hydrophobation of polypeptides and reversible hydrophobic modification of polypeptides are described. The compositions can be used to delivery positively charged, negatively charged and charge neutral polypeptides to cells. ... 02/16/06 - 20060034908 - Manufacturing process for liposomal preparations The present invention provides manufacturing processes for liposomal preparations. In accordance with the methods, a lipid fraction is dissolved in a water-miscible organic solvent. This solution comprising the lipid fraction can be added to and mixed with an aqueous solution under conditions to form a bulk liposomal preparation. Desirably, the ... 02/16/06 - 20060034907 - Method of manufacturing pharmaceutical preparations containing liposomes A method of manufacturing liposome-containing preparations which contain liposomes exhibiting superior stability in vivo and high enclosure rate of a drug is disclosed, comprising mixing a supercritical or subcritical carbon dioxide, one or more liposome membrane constituents including a phospholipid exhibiting a phase transition temperature and a water-soluble chemical. ... 02/16/06 - 20060034906 - Treatment of lung diseases and pre-lung disease conditions In part, the present invention relates to a method of treating lung diseases and pre-lung disease conditions such as precancerous lesions comprising administering to a patient in need a therapeutic agent comprising lipid composition. The present invention also relates to an inhalation device for administering lipid complexes comprising therapeutic agents. ... 02/09/06 - 20060029658 - Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature. ... 02/09/06 - 20060029657 - Topical skin protectant compositions Skin protectant compositions that are free of cholesterol and suitable for topical application to skin of a mammal. In a preferred embodiment, these skin protectant compositions comprise a ceramide; a squalane; a phytosterol-containing liposome; a phospholipid-containing ingredient; at least one triglyceride; and at least one dermatologically acceptable excipient. These compositions ... 02/09/06 - 20060029656 - Replacement enzyme cochleates Disclosed are cochleates and cochleate compositions that associated with an replacement enzyme component and/or a plasmid component that encodes a replacement enzyme. Also disclosed are methods of making and using the compositions of the invention, including methods of administration. Use of the invention provides safe, effective and efficient delivery of ... 02/09/06 - 20060029655 - Method for preparation of vesicles loaded with biological material and different uses thereof The present invention discloses a method for an efficient entrapment of active biological material in liposomes. The method is based on the steps of drying a suspension of liposome-forming lipids and then hydrating the dry composition obtained with an aqueous solution containing a biologically active material to be entrapped in ... 02/02/06 - 20060024360 - Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof The present invention provides compositions that comprise alpha-tocopheryl succinate or its analogue or salt and methods for preparing and using such compositions. ... 02/02/06 - 20060024359 - Drug delivery system and method A method for delivering a therapeutic agent to a predetermined location in a host is disclosed, wherein a liposome-encapsulated therapeutic agent is administered to the host, and an electrical field which encompasses a predetermined region within the host is established, such that as the liposome-encapsulated agent is exposed to the ... 01/12/06 - 20060008519 - Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular ... 01/12/06 - 20060008518 - Sphingomyelin analogues and a process for preparation thereof wherein R1 is C1-20 alkyl group, R2 is C1-20 alkyl group, aryl group or C1-6 alkyl group substituted by aryl group, and Z is photoaffinity-labeled group, or its optically active compound. ... 01/12/06 - 20060008517 - Treatment of age-related memory impairment Symptoms, including biochemical correlates, of age-related memory loss (ARML) in a mammal are beneficially affected by administering to the mammal small doses of bodies, such as liposomes, of a size resembling that of mammalian cells, the bodies having phosphate glycerol head groups presented exteriorly on their surfaces. Preferred are liposomes ... 01/05/06 - 20060002996 - Stable spray-dried protein formulations Spray-dried particles having improved protein stability are produced by spray-drying a mixture including a protein, a phospholipid and an organic-aqueous co-solvent. Spray-dried particles which include at least 1 weight % phospholipid, having a tap density of less than 0.4 g/cm3 can be prepared. The particles can be delivered to the ... 01/05/06 - 20060002995 - Pharmaceutical porous particles The present invention relates to a pharmaceutical, preferably inhalable, porous, free flowing particle to be used in therapeutical application, optionally comprising a therapeutically active compound or substance, whereby the particle consists of one or more network forming compounds, which in diluted solutions self associates to large three dimensional structures having ... 01/05/06 - 20060002994 - Responsive liposomes for ultrasonic drug delivery This invention relates to biotechnology, more particularly, to an improved liposomal drug delivery system. Liposomes treated with or incorporating a surface active dopant, such as those containing polymers or oligomers of ethylene glycol as their hydrophilic “headgroup” component, have strongly increased permeabilizability when exposed to ultrasound. Permeabilizability was measured by ... 01/05/06 - 20060002993 - Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or ... 01/05/06 - 20060002992 - Atomizable liposomes and their use for the pulmonary administration of active substances The present invention discloses a method to prepare specific liposomal formulations for the pulmonary application of therapeutic substances. The liposomal components, DPPC and cholesterol at a molar ratio of 7:3 and 7:4, respectively, are combined with the non-toxic excipients, sphingomyelin, dimyristoylphophatidylcholine and/or polyethylene glycol, to prepare liposomes that are stabile ... 01/05/06 - 20060002991 - Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same wherein Y and X represent linking groups. Furthermore, liposomes are described, which liposomes include said optionally cationic lipids. ... 12/29/05 - 20050287202 - Compound The moiety of interest A may be selected from a carbohydrate moiety, a polymer, a peptide, a glycoprotein, a small biomolecule (such as a folic acid derivative) and a bioconjugate linker. ... 12/29/05 - 20050287201 - Method for delivery of pharmaceuticals for treating or preventing presbyopia Embodiments of the present invention relate to a method for delivering pharmaceuticals to the lens of the eye to treat or prevent presbyopia. According to the embodiments, pharmaceuticals may be applied by providing the pharmaceuticals to the eye and promoting delivery of the pharmaceuticals into the lens capsule and/or lens ... 12/29/05 - 20050287200 - Phospholipid gel compositions for drug delivery and methods of treating conditions using same The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition ... 12/29/05 - 20050287199 - Therapeutic micro nutrient composition for lipolysis and drug delivery An improved formulation and method for the removal of subcutaneous fat deposits in a human in need of such treatment. A lecithin based biphasic injection dosage formulation is disclosed which is applicable to subcutaneous, intramuscular, and intravenous administration. Additionally, a program based approach to the treatment of subcutaneous fat deposits ... 12/29/05 - 20050287198 - Phospholipid gel compositions for drug delivery and methods of treating conditions using same The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition ... 12/29/05 - 20050287197 - Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension is ... 12/29/05 - 20050287196 - Block copolymer micelle composition having an enhanced drug-loading capacity and sustained release The present invention relates to a micelle drug composition having an enhanced drug-loading capacity and improved sustained-release characteristics. The composition comprises an amphilphilic block copolymer wherein at least one hydrophilic blocks and at least one hydrophobic blocks form shell and core, respectively, said hydrophobic block comprises 1.1 to 30 functional ... 12/22/05 - 20050281870 - Pain management k. In which to the substances in (a) to (j) is added Alcohol-H2O Tincture, in a ration of 1:1:1 on all herbal substances in (a) to (j) and concentrated to about a 50% reduction, and to which a final addition of Ascorbyl Palmitate and L-Glutamine in an ½ half to ... 12/15/05 - 20050276843 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human. ... 12/08/05 - 20050271715 - Conjugate having a cleavable linkage for use in a liposome Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The ... 12/08/05 - 20050271714 - Cationic liposome delivery of taxanes to angiogenic blood vessels Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are ... 12/01/05 - 20050266068 - Cardiolipin molecules and methods of synthesis The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reacting a 1,2-O-sn-diacyl/1,2-O-sn-dialkyl glycerol or a 2-O-protected glycerol, with a phosphoramidite reagent or a phosphate triester to produce ... 12/01/05 - 20050266067 - Nanocell drug delivery system Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may ... 12/01/05 - 20050266066 - Phospholipid membrane preparation The present invention aims at providing a phospholipid membrane preparation wherein an antigen or an allergen is bound onto the surface of a phospholipid membrane comprising a phospholipid containing an acyl group or a hydrocarbon group having 10 to 12 carbon atoms, and a stabilizer of a phospholipid membrane. The ... 12/01/05 - 20050266065 - Hydrated lamellar phases or liposomes which contain a fatty monoamine or a cationic polymer which promotes intracellular penetration, and a cosmetic or pharmaceutical composition containing same, as well as a method of screening such a substance The invention relates to novel hydrated lamellar phases or liposomes which contain either polyethylenimine, or a substance which stimulates intracellular penetration selected from the group consisting of: i) a fatty monoamine of carbon-containing chain length of between C10 and C18; ii) a cationic polymer, optionally at least one fluorescent compound ... 12/01/05 - 20050266064 - Cosmetic compositions and methods Methods and compositions are provided for enhancing the size of human lips as well as for reducing fine lines and wrinkles in the skin with topical applications. Methods and compositions are disclosed for increasing blood flow and stimulating collagen synthesis in the skin and surrounding tissues. Methods and compositions are ... 11/24/05 - 20050260261 - Neutral-cationic lipid for nucleic acid and drug delivery wherein each of R1 and R2 is an alkyl or alkenyl chain having between about 8 to about 24 carbon atoms; n=0-20; L is selected from the group consisting of (i) —X—(C═O)—Y—, (ii) —X—(C═O)—, and (iii) —X—CH2—, wherein X and Y are independently selected from oxygen, NH and a direct ... 11/24/05 - 20050260260 - Liposome compositions for the delivery of macromolecules This invention provides for a liposome composition which demonstrates greatly increased therapeutic efficacy when used to deliver encapsulated macromolecular drugs. The liposome composition excludes the use of sterols, sterol derivatives, and cationic lipids, contrary to conventional formulations. The invention liposome is also unique in that it utilizes low gel to ... 11/24/05 - 20050260259 - Compositions for treatment with glucagon-like peptide, and methods of making and using the same In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1. ... 11/24/05 - 20050260258 - Use of vitelline protein b as a microencapsulating additive The present invention includes compositions and methods for the use of an encapsulation additive having between about 0.1 to about 30 percent isolated and purified vitelline protein B to provide for mixed and extended release formulations. ... 11/24/05 - 20050260257 - Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions The invention is directed to therapeutic antioxidant compositions which are enhanced by the stabilized atomic hydrogen; one of the most potent antioxidants. Such products can be used for prophylactic and therapeutic purposes in treatment of cancer, diabetes, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, skin diseases etc. The products described can ... 11/24/05 - 20050260256 - Methods and apparatus for extrusion of vesicles at high pressure This invention relates in general to methods and devices for producing vesicles, including micelles, and particularly liposomes, by extruding solutions comprising materials capable of forming vesicles through a screen membrane at high pressure. ... 11/17/05 - 20050255154 - Method and composition for treating rhinitis A pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprises zwitterionic cetirizine, polar lipid liposome, a pharmaceutical acceptable aqueous carrier and, optionally, a pharmaceutically acceptable buffer capable of providing a pH of from pH 4.0 to pH 8.0, with the proviso that, if the polar lipid ... 11/17/05 - 20050255153 - High efficiency encapsulation of charged therapeutic agents in lipid vesicles Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a ... 11/17/05 - 20050255152 - System for enhanced targeted delivery A method and compositions for targeted drug delivery have been developed. The compositions include a targeting molecules such as a hormone that specifically binds to a receptor on the surface of the targeted cells; a drug to be delivered, such as a toxin that will kill the targeted cells; and ... 11/10/05 - 20050249797 - Self forming, thermodynamically stable liposomes and their applications A lipid composition forms liposomes spontaneously upon mixing with an aqueous solution. The lipid composition includes diacylglycerol-PEG compounds. Such lipid compositions are useful for forming liposomes, which in turn are useful for a variety of purposes, including the delivery of therapeutic agents. ... 11/10/05 - 20050249796 - Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide, ... 11/10/05 - 20050249795 - Gemcitabine compositions for better drug delivery The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped gemcitabine in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds ... 11/10/05 - 20050249794 - Compositions for stimulating cytokine secretion and inducing an immune response Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It has been found that lipid-nucleic acid particles, including those containing non-sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a ... 11/03/05 - 20050244488 - Methods and formulations for enhansing the absorption and gastro-intestinal bioavailability of hydrophobic drugs A hydrophobic drug delivery system that includes a plant derived sterol (stanol), lecithin or a sterol (stanol) derived ester, and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system. ... 11/03/05 - 20050244487 - Membrane architectures for ion-channel switch-based electrochemical biosensors The present invention is directed to a process of forming a bilayer lipid membrane structure by depositing an organic layer having a defined surface area onto an electrically conductive substrate, removing portions of said organic layer upon said electrically conductive substrate whereby selected portions of said organic layer are removed ... 10/27/05 - 20050238707 - Method of cancer treatment This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days ... 10/27/05 - 20050238706 - Pharmaceutically active lipid based formulation of sn-38 SN38, camptothecin derivatives are poorly water soluble, highly lipophilic camptothecin derivatives and are very active against a variety of human cancers. Because of their very poor water solubility, SN38 has not been used to treat human patients with cancer due to the inability to administer sufficient quantities of dissolved in ... 10/27/05 - 20050238705 - Lipid-based dispersions useful for drug delivery The invention provides lipid-based dispersion comprising comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides ... 10/20/05 - 20050232984 - Non-vesicular cationic lipid formulations The present invention relates to a non-vesicular preparation comprising at least one cationic amphiphile in an aqueous environment, its production and use and a cationic liposome suspension obtainable thereof with increase drug trap ratio and its areas of application such as pharmacology and medicine, particularly its use as carrier system ... 10/06/05 - 20050220860 - Stabilized pure vitamin-c in powder to liquid form using multi-encapsulation method Current application relates to a cosmetic powder that contains stabilized pure vitamin C (ascorbic acid) by utilizing ‘multi-encapsulation method.’ Powders of pure vitamin C are well blended with mixtures of glycerin and lecithin to form a liposome of liquid emulsion state. The emulsion, which is comprised of vitamin C, glycerin ... 10/06/05 - 20050220859 - Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (copd) The invention describes a means for the treatment of diseases of the tracheo-bronchial tract, particularly of COPD. ... 10/06/05 - 20050220858 - Method to enhance an immune response of nucleic acid vaccination A composition for the co-delivery to a cell of a nucleic acid and an assistor protein, comprising vesicles, nucleic acid and protein, wherein the nucleic acid operatively encodes an antigenic protein or portion thereof which shares at least one epitope with the assistor protein, the composition comprising said nucleic acid ... 10/06/05 - 20050220857 - Physiologically compatible, phospholipid-containing, stable and hard matrix The invention concerns a physiologically compatible, phospholipid-containing, stable and hard matrix consisting of a supporting material and a bioactive component which has a total diameter of between 0.1 and 5000 μm and contains ≧5% by weight, based on the starting material, of acetone-insoluble components as the bioactive component, which are ... 10/06/05 - 20050220856 - Phospholipid derivative A phospholipid derivative represented by the formula (1) (Z represents a residue of a compound having 3 to 10 hydroxyl groups; AO represents an oxyalkylene group having 2 to 4 carbon atoms; R1CO and R2CO represent an acyl group having 8 to 22 carbon atoms; X represents hydrogen atom, an ... 09/29/05 - 20050214359 - Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination The present invention provides methods and means for preparing vaccines that are capable of eliciting strong immune responses, especially through intranasal delivery. The invention discloses particles, referred to as “co-micelles,” in which antigens are present that interact through hydrophobic interactions with certain specific types of amphiphilic compounds, wherein the amphiphilic ... 09/29/05 - 20050214358 - Composition for promoting development of nervous system An object of the present invention is to provide a composition, a method, a use thereof, or the like for promoting the development of a mammalian nervous system. The present invention provides a composition for promoting the development of a mammalian nervous system, comprising a fatty acid-binding protein (FABP) fraction ... 09/29/05 - 20050214357 - Liposome and preparation method of the same The present invention relates to a composition and a method for preparing a liposome, the liposome including a lipid bilayer and an aqueous core contains a hydrophobic or a hydrophilic drug and a component—Vitamin E derivative (d-α tocopheryl polyethylene glycol 1000 succinate; TPGS). TPGS is able to increase the encapsulation ... 09/29/05 - 20050214356 - Self assembling activation agents targeted using active drug release In a method for therapeutic treatment of humans and other mammals, the therapeutic composition includes a fusogenic encapsulation vesicle and an activation agent such as an organic nanotube or α-DL peptide enclosed in the encapsulation vesicle. The activation agent is maintained in an inactivated form and becomes activated by an ... 09/29/05 - 20050214355 - Washing and chilling apparatus and method Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. ... 09/22/05 - 20050208123 - Chylamydia vaccine Vaccine preparations are provided for the prevention of Chylamydia infections comprising a major outer membrane protein from chlamydia and a mucosal adjuvant such as a combination of QS21 and 3D-MPL, or chlorea Toxin or Heat labile enterotoxin. Such preparations provide protection from Chlamydia induced infertility. ... 09/22/05 - 20050208122 - Biodegradable biocompatible implant and method of manufacturing same Formulations or delivery systems are provided for controlled release of therapeutically active agents. The delivery systems are composed of polymer and lipid materials and may be prepared as a gel, paste, solution, film, implant or barrier depending on the intended application. The polymer component of the matrix is the naturally ... 09/22/05 - 20050208121 - Polymeric cannulae proteins, nucleic acids encoding them and methods for making and using them The invention provides chimeric cannulae polypeptides and methods for making and using them. In one aspect, the invention provides compositions and methods for the identification, separation or synthesis of proteins or ligands. In one aspect, the invention provides compositions and methods for making and using nanotubules. In one aspect, the ... 09/22/05 - 20050208120 - Methods and compositions for isolating, quantifying, characterizing, and modulating antigen-specific t cells The present invention concerns artificial antigen presenting cells (aAPCs) and methods of making and using the same, for example, to isolate, identify, and expand T cell populations specifically reactive against a disease-associated antigenic peptide, as well as to modulate responses of antigen-specific T cells both in vivo, ex vivo, and ... 09/22/05 - 20050208119 - Encapsulated oral chelating preparations This invention provides, in non-limiting embodiments, novel preparations of chelating agents encapsulated in micelles or liposomes comprising the triple combination of: 1) micelles or liposomes comprising alpha lipoic acid or a derivative thereof and 2) micelles or liposomes comprising a chelating agent, such as EDTA; and furthermore, in different embodiments, ... 09/22/05 - 20050208118 - Preparations of encapsulated bioavailable chelating agents for detoxifying humans and animals This invention provides, in non-limiting embodiments, novel preparations of chelating agents encapsulated in micelles or liposomes comprising the triple combination of: 1) micelles or liposomes comprising alpha lipoic acid or a derivative thereof and 2) micelles or liposomes comprising a chelating agent, such as EDTA; and furthermore, in different embodiments, ... 09/15/05 - 20050202078 - Vesicle-encapsulated corticosteroids for the treatment of cancer The invention relates to the use of a composition comprising a corticosteroid encapsulated in a vesicle for the manufacture of a medicament for treating cancer, such as the use of a composition comprising a corticosteroid and liposomes, the liposomes comprising a non-charged vesicle-forming lipid and, optionally, an amphipathic vesicle-forming lipid ... 09/15/05 - 20050202077 - Targeted delivery of rna interference molecules Compositions for the treatment and/or prevention of IgE-mediated disorders in a mammal by means of RNA interference are provided, together with methods for the use of such compounds. The inventive compositions comprise a binding agent that specifically binds to a target internalizable antigen that is expressed on the surface of ... 09/15/05 - 20050202076 - Method of producing a cationic liposomal preparation comprising a lipophilic compound A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed. ... 09/15/05 - 20050202075 - Delivery of genes encoding short hairpin rna using receptor-specific nanocontainers Receptor-specific nanocontainers are used to deliver a gene that encodes short hairpin RNA to cells having a given receptor. Once inside the cell, the gene expresses short hairpin RNA that includes a nucleotide sequence that is antisense to at least a portion of an oncogene, such as human epidermal growth ... 09/15/05 - 20050202074 - Method of administering liposomal encapsulated taxane Liposomal-encapsulated taxane or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer. The liposomal encapsulated paclitaxel allows for administration to a patient, particularly a human patient, in less than one hour without substantial toxicity. ... 09/08/05 - 20050196435 - Method and apparatus for liposome production A new method of producing liposomes is described using an in-line mixing system. The liposomes produced by this method find utility in numerous therapeutic applications. ... 09/01/05 - 20050191345 - Temperature-sensitive liposomal formulation A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the ... 09/01/05 - 20050191344 - Liposome composition for delivery of therapeutic agents A neutral cationic lipid and liposomes prepared from the neutral cationic lipid are described. Liposomes comprised of the lipid are suitable for delivery of a polyanionic compound, such as a nucleic acid. The delivery can be performed in vivo or ex vivo. The neutral cationic lipid, which is neutral in ... 09/01/05 - 20050191343 - Micellar systems useful for delivery of lipophilic or hydrophobic compounds The present invention is directed to reverse micellar formulations for the delivery of hydrophobic or lipophilic compounds, particularly therapeutic compounds. ... 09/01/05 - 20050191342 - Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity Cationic liposomes with immunostimulatory nucleic acids are shown to stimulate the innate immune response, and synergistic combinations of such liposomal nucleic acids and therapeutic antibodies are provided to dramatically improve antibody dependent cellular cytotoxicity and target cell lysis. ... 09/01/05 - 20050191341 - Liposomal composition comprising l-theanine A liposomal encapsulated solution of L-theanine is sprayed onto the sublingual membrane of a subject. The method may be used in the treatment of stress, tension headaches, attention deficit disorder (ADD), attention deficit disorder hyperactivity (ADHD), claustrophobia, hyperactivity, and anxiety. ... 08/25/05 - 20050186266 - Chlamydia antigens and corresponding dna fragments and uses thereof The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a 60 kDa cysteine-rich membrane protein of a strain of Chlamydia pneumoniae. Modifications are possible within the scope of ... 08/25/05 - 20050186265 - Novel cochleate formulations A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a ... 08/25/05 - 20050186264 - Targeting drug/gene carriers to irradiated tissue The present invention provides targeted delivery systems to deliver pharmaceuticals to irradiated tissue comprising a biomolecule carrier, a targeting moiety to cellular adhesion molecules and a pharmaceutical. The present invention also provides methods of selectively targeting endothelial tissue for delivery of a pharmaceutical thereto and of treating a pathophysiological state ... 08/25/05 - 20050186263 - Ph-sensitive polymeric micelles for drug delivery Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers ... 08/18/05 - 20050181039 - Micelles The present invention provides micelles, solutions comprising micelles, methods for preparing micelles, and methods for delivering micelles to patients. The micelles have fixed, preselected hydrodynamic diameters and are formed from basic or acidic amphiphilic compounds. ... 08/18/05 - 20050181038 - Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system The present invention relates to a method of stabilizing a low molecular weight compound in a cationic liposome, wherein said compound has a low solubility in a lipid membrane and/or a low permeability across a lipid membrane. Preferrably, the compound is modified in order to increase lipid membrane solubility and/or ... 08/18/05 - 20050181037 - Cardiolipin compositions their methods of preparation and use The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation. The reaction schemes can be used to generate new forms of cardiolipin, including cardiolipin variants. The cardiolipin prepared by the present methods can conveniently be ... 08/18/05 - 20050181036 - Aerosol delivery of curcumin Pharmaceutical compositions suitable for aerosol delivery to a subject that include curcumin dispersed in a lipid vehicle, wherein the lipid has a transition temperature of less than about 15° C., are disclosed. In addition, methods of treating a pathological condition in a subject that include providing one of the claimed ... 08/18/05 - 20050181035 - Systemic immune activation method using non cpg nucleic acids This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic ... 08/18/05 - 20050181034 - Formulation of liposomal derivatives of phenylalanine The invention relates to pharmaceutical formulations of phenylalanine derivatives and to the use thereof as urokinase inhibitors, in particular for the treatment of malignant tumors and of tumor metastases. ... 08/11/05 - 20050175684 - Targeted iron chelator delivery system A targeted iron chelator delivery system that comprises an iron chelator, a targeting agent and a lipid carrier, e.g., a liposome, is provided. The iron chelator delivery system may be used to remove excess iron from specific organs such as, for example, heart and liver tissue. Methods for preparing and ... 08/11/05 - 20050175683 - Preparation of lipid particles A method for preparing lipid particles comprising producing discrete droplets of vesicle-forming lipids in a solvent, where the droplets have a diameter and a volume, introducing the discrete droplets into an aqueous solution to form lipid particles suitable for in vivo administration. The droplet may further contain any one or ... 08/11/05 - 20050175682 - Polyethyleneglycol-modified lipid compounds and uses thereof The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such compositions, liposomes, SNALP, and SPLP. ... 08/11/05 - 20050175681 - Liposomal vitamin a and method of preparation The invention relates to liposomal vitamin A and method of its preparing. The liposome containing vitamin A as active agent, carriers (supporter) and lipids as adjuvents and liposome-forming materials. The process comprises: adding vitamin A and lipids to carriers, forming a liposomal vitamin A in the form of solid, then ... 08/04/05 - 20050169980 - Therapeutic liposome composition and method of preparation Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, ... 08/04/05 - 20050169979 - Liposomal vaccine The invention provides liposomal vehicles for encapsulating relatively high levels of immunogenic protein substances including immunogens directed against hormones and hormone receptors, such as gastrin and gonadotropin releasing hormone and their receptors. The liposome encapsulating large amounts of immunogens can be injected parenterally to induce effective immune responses without exhibiting ... 08/04/05 - 20050169978 - Wet-micro grinding This invention relates to a method for preparing a drug-lipid complex that does not have a captured volume or a drug-containing liposome. The method includes dispersing a drug and one or more phospholipids in an aqueous solution to obtain a mixture and grinding the mixture with a mechanic means to ... 07/28/05 - 20050163832 - Intracellular delivery of therapeutic agents The preparation and use of a transducing polypeptide (TP)— lipid vesicle complex having a small proportion of positively charged (cationic) lipids in the make-up of the lipid vesicle, e.g., liposome, for safe and efficient intracellular delivery of therapeutic agents, such as proteins, DNA, small molecules and/or other drugs, into a ... 07/21/05 - 20050158375 - Pharmaceutical composition containing liposomes for treating cancer The present invention provides liposome-containing drug administration carriers that have improved residence time in the blood and improved migration into tumor cells as compared with conventional ones and that have reduced accumulation in the heart, and a pharmaceutical composition for treating a cancer that includes liposomes containing an antitumor active ... 07/21/05 - 20050158374 - Compositions and dosage forms for enhanced absorption of metformin A complex comprised of metformin and a transport moiety, such as a fatty acid, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The complex, and compositions and dosage forms prepared using the complex, provide for absorption by the body of the ... 07/21/05 - 20050158373 - Method and carrier complexes for delivering molecules to cells The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In ... 07/21/05 - 20050158372 - Immunoliposome-nucleic acid amplification (ilnaa) assay Immunoliposomes and use thereof in highly specific and sensitive nucleic acid amplification assays relying on amplification of specific nucleic acid sequences released from encapsulation within a liposome after a receptor on the liposome couples with a targeted analyte/antigen immobilized on a select surface. The immunoliposome nucleic acid amplification assay permits ... 07/14/05 - 20050152964 - Stable lipid-comprising drug delivery complexes and methods for their production Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention ... 07/14/05 - 20050152963 - Liposome compositions and a compound of the formula Z-Y, wherein Z is any compound capable of binding to a cellular receptor, and X and Y are compounds which can interact with each other non-convalently, and wherein the substituents n, F1 and F2 are as provided in the specification. ... 07/14/05 - 20050152962 - Composition for treatment of inflammatory disorders A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than five (5) mole percent of charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the ... 07/14/05 - 20050152961 - Biological bioadhesive compositions and methods of preparation and use The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the ... 07/14/05 - 20050152960 - Use of green porphyrins to treat neovasculature in the eye Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions. ... 07/14/05 - 20050152959 - Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell The present invention relates to the use of at least one lysolipid for the preparation of a composition for improving transfection or transduction of a polynucleotide into a cell. Such a composition is useful in gene therapy, vaccination, and any therapeutic or prophylactic situation in which a gene-based product is ... 07/07/05 - 20050147661 - Gelatin derivatives and high-molecular micelle comprising the derivatives The present invention relates to a gelatin derivative having an organic compound as a graft chain and a high-molecular weight micelle containing the gelatin derivative. As the organic compound, a low molecular weight compound such as succinic acid, ethylenediamine, etc., or a high-molecular weight compound such as polyethylene glycol, polylactic ... 07/07/05 - 20050147660 - Peptide-carrying bodies for immune response A composition of matter capable of producing an anti-inflammatory response in vivo in a mammal comprises bodies having a three-dimensional core structure of conformation and size from about 20 nm to about 500 μm and expressing or expressible on the surface thereof RGDS ligands which will react, optionally in the ... 07/07/05 - 20050147659 - Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support Pharamaceutical compositions in the form of powders or microgranules, comprising an oil/water/oil double microemulsion incorporated into a solid support constituted by a microporous inorganic substance or by an adsorbent inorganic colloidal substance or by a cross-linked swellable in water polymer. ... 06/30/05 - 20050142184 - Emulsion formulations for hydrophilic active agents This invention discloses emulsion formulations comprising an aqueous carrier and the following components: triglyceride, cholesterol, phospholipid, at least one charged lipid, at least one hydrophilic biologically active molecule and, optionally, cholesteryl ester, and/or apoprotein; methods of preparing these emulsions; and the use of these emulsions as vehicles for the delivery ... 06/30/05 - 20050142183 - Recombinant mistletoe lectin The present invention relates to processes for the production of mistletoe lectin polypeptides in homologous and heterologous host systems and mistletoe lectin peptides as such. Further, nucleic acid molecules are provided, which code for these mistletoe lectin polypeptides, and also pharmaceutical compositions which contain these mistletoe lectin polypeptides or mistletoe ... 06/30/05 - 20050142182 - Long circulating liposome The present invention relates to a liposome having a phospholipid bilayer and a hydrophilic core, wherein the phopspholipid bilayer contains D-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS). The liposomes are first prepared by solvent injection and extrusion method, and then drug loading by ammonium sulfate gradient. The TPGS in the ... 06/30/05 - 20050142181 - Targeted delivery system A targeting delivery system. The targeted delivery system includes a carrier for a drug and a targeted ligand modifying the carrier to target the encapsulated drug to a sigma receptor over-expressed cell. ... 06/30/05 - 20050142180 - Pharmaceutical formulations, methods, and dosing regimens for the treatment and prevention of acute coronary syndromes The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano: phospholipid complex to reduce and stabilize atherosclerotic plaque. Pharmaceutical formulations of the Apo A-I Milano:phospholipid complexes are also provided. ... 06/30/05 - 20050142179 - Transfection reagents The present invention provides optimized transfection reagents comprising mixtures of cationiclipoids. In particular, the present invention provides DNA delivery vehicles based on identifying the optimal hydrophobicity of novel cationic phospholipid derivatives that, alone or in combination, form complexes with DNA (lipoplexes) and exhibit enhanced transfection activity. ... 06/30/05 - 20050142178 - Non-pegylated long-circulating liposomes The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found ... 06/30/05 - 20050142177 - Pain management k. A transdermal Liposomal carrier adapted to act as a transdermal carrier in which the substances (a) to (j) are combined with Alcohol-H2O Tincture, with a ratio of 1 to 1 to 1 on all herbal components and concentrated to about 50% reduction, to a final addition of Ascorbyl Palmitate ... 06/16/05 - 20050129754 - Injectable anesthetic formulation An injectable anesthetic formulation. The formulation contains a halogenated anesthetic in an amount not greater than approximately 24% v/v of the formulation and an emulsification adjuvant in an amount from approximately 8% to approximately 32% v/v of the formulation. In addition, the formulation contains lecithin in an amount from approximately ... 06/16/05 - 20050129753 - Method for drug loading in liposomes A liposome composition having a protonatable therapeutic agent entrapped in the form of a salt with an glucuronate anion is disclosed. Methods for preparing the composition using an ammonium ion transmembrane gradient having glucuronate as the counterion are also disclsoed. In one embodiment where the protonatable agent is doxorubicin, the ... 06/16/05 - 20050129752 - Use and manufacturing process for liposomal doxorubicin pharmaceutical composition The present invention provides a method of treating mammals having pancreatic cancer by administering a liposomal doxorubicin pharmaceutical composition, and a process of manufacturing the composition. ... 06/16/05 - 20050129751 - Drug delivery compositions and methods Contemplated drug delivery systems allow controlled release of a drug in a manner that is independent of the physicochemical parameters of both the drug and its carrier. In one preferred aspect, the drug and the carrier are released from a second carrier that has a predefined release characteristics, which is ... 06/16/05 - 20050129750 - Process for producing liposome suspension and product containing liposome suspension produced thereby A process for the large scale production of a liposome suspension, in which three selected lipid compounds in a predetermined ratio are dissolved in an alcohol solvent to form a mixture, which, in turn, is directly admixed with an aqueous ammonium sulfate solution in a predetermined ratio. The resultant mixture ... 06/09/05 - 20050123600 - Compositions and methods for drug delivery using ph sensitive molecules An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to ... 06/09/05 - 20050123599 - Immunological adjuvant compositions The present invention is directed to novel adjuvant compositions, which target the cellular and/or humoral arms of immunity. According to an embodiment of the invention, an oil-in-water adjuvant composition is provided that comprises: (a) water; (b) a metabolizable oil comprising at least one branched or unbranched long-chain hydrocarbon moiety; (c) ... 06/09/05 - 20050123598 - Apoptosis-mimicking synthetic entities and use thereof in medical treatment Synthetic and semisynthetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed ... 06/09/05 - 20050123597 - Releasable linkage and compositions containing same A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described. ... 06/09/05 - 20050123596 - Ph-triggered microparticles Microparticles that are designed to release their payload when exposed to acidic conditions are provided as a vehicle for drug delivery. Any therapeutic, diagnostic, or prophylatic agent may be encapsulated in a lipid-protein-sugar or polymeric matrix including a pH triggering agent to form pH triggerable microparticles. Preferably the diameter of ... 06/09/05 - 20050123595 - Composition for removing tattoos A composition and method for removing tattoos is disclosed. The method includes administering a composition including a photosensitiser to the skin area comprising the tattoo, allowing the histiocytes in the dermis of the tattoo area to take up the phtosensitiser, and illuminating the treated skin area to induce production of ... 06/09/05 - 20050123594 - Liposomes for protection against toxic compounds Generally, and in one form, the present invention is a method of method of preparing a proteoliposome comprising the step of contacting a liposome with an effective portion of RLIP76 to create a proteoliposome. In another form, the present invention is a proteoliposomal composition comprising a liposome and an effective ... 06/09/05 - 20050123593 - Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints In a preferred embodiemnt the present invention features a composition and method of delivery comprising Glycosaminoglycans encapsulated in a liposomal delivery system for intraarticular administration for the treatment of osteoarthritis In a more preferred embodiemnt the present invention features a composition and method of delivery comprising hyaluronic acid encapsulated in ... 06/02/05 - 20050118253 - Systemic delivery of serum stable plasmid lipid particles for cancer therapy The present invention relates to methods and compositions for treating a neoplasia in a mammal. ... 06/02/05 - 20050118252 - Tumor environment-induced ligand-expressing nanocarrier system Drug delivery compositions for specific delivery of a drug to a tumor are described. These compositions include a core for sequestering the drug and a shell to which a ligand is attached for delivery of a drug to target cells. Since normal cells may also be targeted by the ligand, ... 06/02/05 - 20050118251 - Novel dna-based vaccine against the encephalitis alphaviruses This invention relates to the development of a mammalian expression vector, under which expression of the structural genes of western equine encephalitis virus have been placed under the control of an eucaryotic promoter. When the recombinant vector is administered to mammalian cell culture or using a cell-free transcription/translation system, in ... 06/02/05 - 20050118250 - Lipid carrier compositions with enhanced blood stability Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to an non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely. ... 06/02/05 - 20050118249 - Lipid carrier compositions and methods for improved drug retention Liposomal compositions which have enhanced retention properties for biological agents are characterized by an intrasomal osmolarity of 500 mOSM/kg or less and by containing substantially no cholesterol. The liposomes comprise vesicle forming lipids along with aggregation preventing components, and typically have transition temperatures of 38° C. or higher. ... 06/02/05 - 20050118248 - Amphiphilic derivatives for the production of vesicles, micelles and complexants, and precursors thereof Amphiphilic derivatives composed of at least one fatty acid chain are derived from natural vegetable oils such as vernonia oil, lesquerella oil and castor oil, in which the several reactive groups such as epoxy, hydroxy and double bonds can be modified to polar and ionic groups. The head group of ... ### FreshPatents.com Support |